⌘K
t
Creo Medical Group plc announced that Fiduchi Trustees, trustee for its Share Incentive Plan (SIP), acquired 228,940 ordinary shares at £0.14 each on 22 July 2025 for SIP participants. Additionally, 457,880 existing unallocated ordinary shares within the SIP were utilised to meet matching share obligations, meaning no new company shares were issued. On 22 July 2025, executive directors Craig Gulliford and Richard Rees each acquired 6,429 Partnership Shares at £0.14 and received 12,858 Matching Shares at £0.001.
| Date | 24 Jul 2025 |
| Time | 07:00:11 |
| Category | Director/PDMR dealings |
| ID | 3264S |
Creo Medical Group plc
("Creo" the "Company" or the "Group")
Award of Shares under Share Incentive Plan and Director Dealings
Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, implemented an HMRC approved Share Incentive Plan ("SIP") during 2020, which is available to all of the Company's UK based employees, including Directors.
The Company has been notified that Fiduchi Trustees (UK) Limited ("Fiduchi"), the independent trustee of the SIP, acquired, in accordance with the SIP's rules and on behalf of SIP participants, 228,940 ordinary shares in the Company ("Ordinary Shares"), at a price of £0.14 per Ordinary Share on 22 July 2025 to meet its obligations under the SIP (the "Partnership Shares"). Under the terms of the SIP, the Company is required to issue or make available to the SIP two Ordinary Shares in the Company for each Partnership Share purchased (being 457,880 Ordinary Shares in total for the six-month period to end of June 2025, the "Matching Shares"). Fiduchi currently holds 2,664,126 unallocated Ordinary Shares within the SIP which can be utilised to satisfy the Company's obligation to issue or make available Matching Shares. Accordingly, 457,880 Ordinary Shares will be utilised by Fiduchi as trustee of the SIP to meet this matching obligation, and no new Ordinary Shares are required to be issued to satisfy the Company's obligations under the SIP.
Craig Gulliford and Richard Rees, executive directors of the Company (the "Participating Directors"), have acquired Partnership Shares at a price of £0.14 per share and received Matching Shares at a price of £0.001 per share in accordance with terms of the SIP (the "Transaction"). Following the Transaction, the Participating Directors' shareholdings in the Company are as set out in the table below:
|
Director |
Total number of Ordinary Shares purchased or awarded under SIP |
Total number of Ordinary Shares held post Transaction |
|
Craig Gulliford, CEO |
19,287 |
1,686,1941 |
|
Richard Rees, CFO |
19,287 |
3,069,9632 |
The notifications below, made in accordance with the requirements of the Market Abuse Regulation, provide further detail in relation to the award of the SIP Shares to the Participating Directors.
Notes:
1 Includes shares held by Mr Gulliford's wife.
2 Includes shares held by Mr Rees's wife and PCAs.
For further information please contact:
|
Creo Medical Group plc |
||
|
Richard Craven, Company Secretary |
Via Walbrook PR |
|
|
|
|
|
|
Deutsche Numis (Nominated Adviser, Broker and Financial Adviser) Freddie Barnfield / Duncan Monteith / Sher Shah |
+44 (0)20 7260 1000 |
|
|
|
|
|
|
Walbrook PR Ltd |
Tel: +44 (0)20 7933 8780 or [email protected] |
|
|
Paul McManus / Alice Woodings
|
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 |
|
About Creo Medical
Creo is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.
The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation, and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less invasive and more cost-efficient option for procedures.
For more information, please refer to the website www.creomedical.com
|
1. Details of PDMR |
||||||
|
a) |
Name |
Craig Gulliford |
||||
|
b) |
Position / status |
CEO |
||||
|
c) |
Initial notification / amendment |
Initial notification |
||||
|
2. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||
|
a) |
Description of the financial instrument |
Ordinary Shares |
||||
|
b) |
Nature of the transaction |
Purchase of Ordinary Shares under Share Incentive Plan
|
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information
Aggregated volume Price |
N/A - Single transaction
|
||||
|
e) |
Date of the transaction |
2025-07-22 BST |
||||
|
f) |
Place of the transaction |
London Stock Exchange |
||||
|
1. Details of PDMR |
||||||
|
a) |
Name |
Craig Gulliford |
||||
|
b) |
Position / status |
CEO |
||||
|
c) |
Initial notification / amendment |
Initial notification |
||||
|
2. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||
|
a) |
Description of the financial instrument |
Ordinary Shares |
||||
|
b) |
Nature of the transaction |
Award of Ordinary Shares (Matching Shares) under Share Incentive Plan
|
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information
Aggregated volume Price |
N/A - Single transaction
|
||||
|
e) |
Date of the transaction |
2025-07-22 BST |
||||
|
f) |
Place of the transaction |
Off-market |
||||
|
1. Details of PDMR |
||||||
|
a) |
Name |
Richard Rees |
||||
|
b) |
Position / status |
CFO |
||||
|
c) |
Initial notification / amendment |
Initial notification |
||||
|
2. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||
|
a) |
Description of the financial instrument |
Ordinary Shares |
||||
|
b) |
Nature of the transaction |
Purchase of Ordinary Shares under Share Incentive Plan
|
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information
Aggregated volume Price |
N/A - Single transaction
|
||||
|
e) |
Date of the transaction |
2025-07-22 BST |
||||
|
f) |
Place of the transaction |
London Stock Exchange |
||||
|
1. Details of PDMR |
||||||
|
a) |
Name |
Richard Rees |
||||
|
b) |
Position / status |
CFO |
||||
|
c) |
Initial notification / amendment |
Initial notification |
||||
|
2. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||
|
a) |
Description of the financial instrument |
Ordinary Shares |
||||
|
b) |
Nature of the transaction |
Award of Ordinary Shares (Matching Shares) under Share Incentive Plan
|
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information
Aggregated volume Price |
N/A - Single transaction
|
||||
|
e) |
Date of the transaction |
2025-07-22 BST |
||||
|
f) |
Place of the transaction |
Off-market |
||||